BACKGROUND:Patients with tubulointerstitial nephritis (TIN) may develop permanent renal impairment. However, there are no prospective studies available on the treatment of TIN. METHODS: The effect of prednisone in the treatment of TIN was evaluated in a total of 17 patients who received prednisone or who were followed up without medication. The patient group was subdivided based on the initial plasma creatinine (PCr), below or above 150 μmol/l. RESULTS: All prednisone-treated patients had normal plasma creatinine (PCr) after 1 month of treatment (median 59.1 [45-85] μmol/l) whereas only 50 % of patients in the non-treatment group had normal creatinine (median 81.0 [42-123] μmol/l) at the same time point (p = 0.025). During 6 months' follow-up, PCr decreased in all patient groups; however, it decreased significantly only in prednisone-treated patients with baseline PCr >150 μmol/l (p < 0.001). At the end of follow-up, no difference in PCr, glomerular filtration rate (GFR), or low molecular weight (LMW) proteinuria could be found between the study groups. A considerable number of patients in both groups had subnormal GFR and/or persistent LMW proteinuria at the 6-month follow-up visit. Eighty-two percent of the patients had uveitis. CONCLUSIONS:Prednisone speeds up the recovery from renal symptoms of TIN, especially in patients with severe nephritis. The renal function did not differ significantly between prednisone and control patients after 6 months' follow-up.
RCT Entities:
BACKGROUND:Patients with tubulointerstitial nephritis (TIN) may develop permanent renal impairment. However, there are no prospective studies available on the treatment of TIN. METHODS: The effect of prednisone in the treatment of TIN was evaluated in a total of 17 patients who received prednisone or who were followed up without medication. The patient group was subdivided based on the initial plasma creatinine (PCr), below or above 150 μmol/l. RESULTS: All prednisone-treated patients had normal plasma creatinine (PCr) after 1 month of treatment (median 59.1 [45-85] μmol/l) whereas only 50 % of patients in the non-treatment group had normal creatinine (median 81.0 [42-123] μmol/l) at the same time point (p = 0.025). During 6 months' follow-up, PCr decreased in all patient groups; however, it decreased significantly only in prednisone-treated patients with baseline PCr >150 μmol/l (p < 0.001). At the end of follow-up, no difference in PCr, glomerular filtration rate (GFR), or low molecular weight (LMW) proteinuria could be found between the study groups. A considerable number of patients in both groups had subnormal GFR and/or persistent LMW proteinuria at the 6-month follow-up visit. Eighty-two percent of the patients had uveitis. CONCLUSIONS:Prednisone speeds up the recovery from renal symptoms of TIN, especially in patients with severe nephritis. The renal function did not differ significantly between prednisone and control patients after 6 months' follow-up.
Authors: Michael R Clarkson; Louise Giblin; Fionnuala P O'Connell; Patrick O'Kelly; Joseph J Walshe; Peter Conlon; Yvonne O'Meara; Anthony Dormon; Eileen Campbell; John Donohoe Journal: Nephrol Dial Transplant Date: 2004-08-31 Impact factor: 5.992
Authors: E González; E Gutiérrez; C Galeano; C Chevia; P de Sequera; C Bernis; E G Parra; R Delgado; M Sanz; M Ortiz; M Goicoechea; C Quereda; T Olea; H Bouarich; Y Hernández; B Segovia; M Praga Journal: Kidney Int Date: 2008-01-09 Impact factor: 10.612
Authors: Sari H Rytkönen; Petri Kulmala; Helena Autio-Harmainen; Pekka Arikoski; Kira Endén; Janne Kataja; Tuomo Karttunen; Matti Nuutinen; Timo Jahnukainen Journal: Pediatr Nephrol Date: 2017-09-11 Impact factor: 3.714
Authors: Sari Rytkönen; Jarmo Ritari; Juha Peräsaari; Ville Saarela; Matti Nuutinen; Timo Jahnukainen Journal: PLoS One Date: 2019-02-19 Impact factor: 3.240
Authors: Sarah Wente-Schulz; Marina Aksenova; Atif Awan; Cahyani Gita Ambarsari; Francesca Becherucci; Francesco Emma; Marc Fila; Telma Francisco; Ibrahim Gokce; Bora Gülhan; Matthias Hansen; Timo Jahnukainen; Mahmoud Kallash; Konstantinos Kamperis; Sherene Mason; Antonio Mastrangelo; Francesca Mencarelli; Bogna Niwinska-Faryna; Michael Riordan; Rina R Rus; Seha Saygili; Erkin Serdaroglu; Sevgin Taner; Rezan Topaloglu; Enrico Vidal; Robert Woroniecki; Sibel Yel; Jakub Zieg; Lars Pape Journal: BMJ Open Date: 2021-05-28 Impact factor: 2.692